Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China flag China · Delayed Price · Currency is CNY
9.31
+0.11 (1.20%)
Sep 14, 2026, 3:04 PM CST

Yifan Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
303.4402.02385.97-551.07191.22278.4
Depreciation & Amortization
342.49344.12335.67270.6228.43207.18
Other Amortization
15.7818.169.939.219.486.88
Loss (Gain) From Sale of Assets
-7.31-12.7-30.15-2.570.56-14.83
Asset Writedown & Restructuring Costs
27.4230.3773.69872.46102.1338.25
Loss (Gain) From Sale of Investments
25.1627.3114.1615.0617.634.49
Provision & Write-off of Bad Debts
33.1222.7561.6360.4729.1221.34
Other Operating Activities
74.6454.5137-237.8938.4456.52
Change in Accounts Receivable
184.81-109.04-363.72-10.25-103.77-18.59
Change in Inventory
43.74-202.11-147.75-109.39-167.1-80.48
Change in Accounts Payable
-219.6-115.23239.9962.88156.63-99.34
Change in Other Net Operating Assets
-13.5818.0519.7121.7923.15-10.3
Operating Cash Flow
765.78458.37640.73348.58472.07301.23
Operating Cash Flow Growth
-2.21%-28.46%83.81%-26.16%56.71%-72.82%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-688.07-559.23-628.16-504.09-542.27-571.74
Sale of Property, Plant & Equipment
28.424.410.325.027.8417.7
Cash Acquisitions
------42
Divestitures
--5.291.061.215.9
Investment in Securities
-0.2880.5975-39.13-137.5866.6
Other Investing Activities
-0.210.132.674.30.655.64
Investing Cash Flow
-660.16-454.09-544.88-532.84-670.17-507.89

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
-1,8572,0011,8551,7892,928
Long-Term Debt Repaid
--1,800-1,709-2,044-1,897-2,448
Lease Payments
-22.55-23.48-16.6-21.28-16.84-15.46
Net Debt Issued (Repaid)
166.1257.38291.87-189.38-107.72480.27
Issuance of Common Stock
----0.851
Repurchase of Common Stock
----38-53.56-121.47
Common Dividends Paid
-171.1-171.58-194.81-72.47-86.38-138.39
Other Financing Activities
-20.020.0315.67330.62234.150.75
Financing Cash Flow
-24.99-114.17112.7330.78-12.66222.16

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-43.96-3.97-3.6914.5959.56-20.85
Net Cash Flow
36.68-113.87204.89-138.88-151.2-5.36

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
77.71-100.8712.57-155.5-70.21-270.51
Free Cash Flow Growth
-52.35%-----
Free Cash Flow Margin
1.57%-1.97%0.24%-3.82%-1.83%-6.13%
Free Cash Flow Per Share
0.06-0.080.01-0.13-0.06-0.22
Levered Free Cash Flow
38.96-56.25-194.48-168.05-347-430.33
Unlevered Free Cash Flow
70.37-23.1-151.29-120.83-293.35-383.71
Free Cash Flow After Leases
55.16-124.35-4.03-176.78-87.05-285.96

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
314.75368.39321.69362.2291.5220.66
Change in Working Capital
-48.91-428.18-247.18-87.68-144.96-295.73